Oncology clinical trials at Subiaco
- Cancer is the leading cause of death in Australia, with about 1 in 2 Australian men and 1 in 3 Australian women will be diagnosed with cancer in their life.
- Clinical trials play an essential role in discovering new and more effective treatments for cancer.
- Outstanding research-based health care is provided to all participants involved in clinical trials and we offer comprehensive and integrated evidence-based treatment options.
- Since 2001 the Oncology Clinical Trial Unit at St John of God Subiaco Hospital in collaboration with Cancer Council WA has focused on providing different treatment options, in addition to the standard of care, for people with a wide variety of cancers.
- We are committed to ensuring our research provides opportunities and support for patients undergoing treatment for their cancer that may otherwise not be available in a non-clinical trial setting. Additionally results from these studies will inform future bedside care and hopefully improve patient outcomes. This focus has helped us become one of Australia’s top research institutes.
Dr Andrew Dean
A/Prof Timothy Clay
Dr Tom van Hagen
Dr Tarek Meniawy
Dr Daphne Tsoi
Dr Martin Buck
Dr Mihitha Ariyapperuma
Prof Christobel Saunders
A/Prof Paul Cohen
Dr Janelle Prunster
Dr Shaun Ong
Research Operations Manager
Research Administrative Officer
Senior Clinical Trial and Data Management Officer
Clinical Trial and Data Management Officers
Clinical Trial Nurse, Oncology
Clinical Trials Assistant
Dr Niloufer Johansen, Research Officer (Breast)
Dr Katy Mohammadi (Breast)
Stephanie Jeffares (Gynaecology Cancer)
Clinical Trial Liaison Officer
Dr Angela Baird
Project Manager, Clinical Trial Development
Dr Jo Youd
Dean, A., Peeperkon, L., Armstrong, K., De Marie, A., Watanabe, Y., Tan, M., Travers, N. Prospective evaluation of FOLFIRINOX in neo-adjuvant treatment of gastro-oesophageal junction carcinomas. Annals of Oncology, 2 July 2019
Dean, A., McNulty, M., Das, A. Third-line re-treatment of advanced pancreatic adenocarcinoma with gemcitabine and nab-paclitaxel. Annals of Oncology, Volume 30, 2 July 2019
Dean, A., Das, A. Modifi ed FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma following gemcitabine plus nab-paclitaxel failure in patients with status two or less. Annals of Oncology, Volume 30, 2 July 2019
You may be interested in